Alphabetic Index FY2027

C74.91

Malignant neoplasm of unspecified part of right adrenal gland

FY2027Chapter 2: Neoplasms/C73–C75 Malignant neoplasms of thyroid and other endocrine glands

BillableComplete code, valid to report
    Care settingsHome Health Primary · MMTA - Infectious Disease, Neoplasms, and Blood-Forming DiseasesHospital CCIPF Comorbidity · Oncology Treatment

    C74.91 (also written C7491) is a billable ICD-10-CM diagnosis code for malignant neoplasm of unspecified part of right adrenal gland. It is part of the FY2027 code set, effective October 1, 2026. It is one of the 9 codes in category C74 (Malignant neoplasm of adrenal gland).

    Guidelines tip

    From the FY2027 Official Guidelines. ICD10Ref adds no rules of its own.

    A primary malignancy code stays in use until treatment directed at that site is completed. After that, with no evidence of disease at the site, Z85 gives the former site.

    Guidelines I.C.2.mCurrent malignancy versus personal history of malignancyRead the official text

    Care settings

    How CMS programs treat this code. These are CMS claim edits and list entries, not coverage or eligibility rules.

    Home Health Primary

    Accepted as the primary (principal) diagnosis on a home health claim. The Home Health Grouper assigns it to the MMTA - Infectious Disease, Neoplasms, and Blood-Forming Diseases clinical group.

    Source: CMS Home Health Grouper Software v07.2.26, effective October 1, 2026

    Hospital CC

    Counts as a complication or comorbidity (CC) when reported as a secondary diagnosis on an inpatient claim. It does not count when the principal diagnosis is one of the 25 codes in its exclusion list. Some MS-DRGs also ignore a CC or MCC that defines the DRG.

    Source: CMS MS-DRG Definitions Manual v44, effective October 1, 2026, Appendix C

    IPF Comorbidity

    On the CMS IPF comorbidity list.

    Comorbidity categoryFactor
    Oncology Treatment1.44
    It counts as a comorbidity when reported as a secondary diagnosis and actively treated during the stay. An IPF receives only one adjustment within a category and can receive adjustments in more than one category.

    Source: CMS IPF PPS FY 2027 final rule (CMS-1847-F), Addendum B-3 (comorbidity codes with adjustment factor); effective for discharges on or after October 1, 2026

    Notes

    Also from chapter/block level (8 notes)
    Inherited from Chapter 2 Neoplasms
    • Functional activity
    • All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm.
    • Morphology [Histology]
    • Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, etc. The Table of Neoplasms should be used to identify the correct topography code. In a few cases, such as for malignant melanoma and certain neuroendocrine tumors, the morphology (histologic type) is included in the category and codes.
    • Primary malignant neoplasms overlapping site boundaries
    • A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous, such as tumors in different quadrants of the same breast, codes for each site should be assigned.
    • Malignant neoplasm of ectopic tissue
    • Malignant neoplasms of ectopic tissue are to be coded to the site mentioned, e.g., ectopic pancreatic malignant neoplasms are coded to pancreas, unspecified (C25.9).